Whats new
Whats new.
Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)
March 25th 2025
For a copy of this research report please contact your Baird advisor
Whats new
March 25th 2025
For a copy of this research report please contact your Baird advisor